Onesource Specialty Pharma has announced a significant corporate development involving the creation of a share pledge by Catalyst Trusteeship Limited. The pledge covers 64,00,000 equity shares of the pharmaceutical company, representing a substantial portion of its shareholding structure.

Share Pledge Details

The pledge arrangement involves specific parameters that highlight the scale of the transaction:

Debenture Issuance Connection

The share pledge has been established specifically in connection with a ₹1,000.00 crore debenture issuance by Onesource Specialty Pharma Ltd. This substantial debt instrument represents a significant financing initiative by the company, with the pledged shares serving as security for the debenture holders.

Corporate Implications

The creation of this pledge indicates the company's engagement in debt financing activities through the capital markets. Catalyst Trusteeship Limited's role as the pledgee suggests a structured approach to securing the debenture issuance, providing additional protection for investors in the debt instrument.

The 5.59% shareholding pledge represents a meaningful portion of the company's equity base, demonstrating the substantial nature of the underlying debenture transaction and the security arrangements put in place to support this ₹1,000.00 crore financing initiative.

OneSource Specialty Pharma Limited has disclosed the creation of an encumbrance over 64,00,000 equity shares by Tenshi Pharmaceuticals Private Limited in favor of Catalyst Trusteeship Limited. The disclosure was made under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 on January 07, 2026.

Pledge Details and Structure

The pledge was created as security for zero coupon, secured, unrated, unlisted, redeemable non-convertible debentures worth ₹1000,00,00,000 issued by Karuna Ventures Private Limited. Karuna Ventures is a group company of Tenshi Pharmaceuticals, which serves as the pledgor in this transaction.

Shareholding Pattern and Background

Tenshi Pharmaceuticals Private Limited holds 2,05,24,714 equity shares in OneSource Specialty Pharma Limited, constituting 17.92% of the company's issued and paid-up share capital. The total equity share capital of OneSource remains unchanged at 11,45,25,216 paid-up equity shares of ₹1 each before and after this encumbrance.

Progressive Pledge Creation

The current disclosure represents the second tranche of share pledging under the debenture arrangement. Previously, on December 16, 2025, Tenshi Pharmaceuticals had created a pledge over 20,00,000 equity shares constituting 1.75% of the issued share capital. The recent pledge of 44,00,000 additional shares on January 05, 2026, brings the total pledged shares to 64,00,000.

Regulatory Framework

The pledge was executed pursuant to a debenture trust deed and share pledge agreement both dated November 27, 2025. Under the takeover regulations, encumbrance over shares is treated as an acquisition, necessitating this disclosure. Catalyst Trusteeship Limited acts as the debenture trustee for the benefit of debenture holders, including their assigns, transferees, successors, and novatees.

Company Information

OneSource Specialty Pharma Limited is listed on both BSE Limited and National Stock Exchange of India Limited. The company's registered office is located at Cyber One, Unit No. 902, Sector 30A, Plot No. 4 & 6, Vashi, Navi Mumbai – 400703. Catalyst Trusteeship Limited, serving as the debenture trustee, does not belong to the promoter or promoter group of OneSource Specialty Pharma Limited.